Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

2.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Benzene in Cold Med; Male Cancer Death to Rise 93%; Mail-Order Drugs Compromised?

5.

New research demonstrates a method for screening people at high risk for pancreatic cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot